Amrubicin(SM-5887) is a novel anthracycline derivative for treatment of bladder carcinoma.
Target: Others
Amrubicin (SM-5887) is an anthracycline used in the treatment of lung cancer. The distribution of SM-5887 in the bladder mucosa and muscular layer was almost equal, but the concentration of its active metabolite, 13-OH derivative, was 5 to 10 times higher in the bladder mucosa than in the bladder muscular layer. The distributions of SM-5887 in the organs other than the bladder, that is, the cortex and medulla of kidney, heart, lung, liver, and spleen, were very low, and those of a 13-OH active metabolite were even lower. In addition, SM-5887 barely affected the normal bladder mucosa. In dogs instilled with 80 mg of SM-5887, no histological change was observed in the bladder mucosa and submucosal layer even after 6-hour retention at the highest concentration of 8,000 micrograms/ml [1]. phase II clinical trial of SM-5887, a new totally synthesized anthracycline derivative, was carried out in 13 patients with inoperable or recurrent gastric cancer. No patient had been given anthracycline previously. SM-5887 was administered by I.V. bolus with a dose of 100 mg/m2 every three weeks. Twelve of 13 cases were eligible and evaluable for the response. Of the 12 evaluated cases, 6 showed no change (NC), including one minor response (MR) [2].

(20S)-Protopanaxatriol  (20S)-Protopanaxatriol(g-PPT) is a metabolites of ginsenoside, protopanaxatriol (g-PPT), could modulate endothelial cell functions through the glucocorticoid receptor (GR) and oestrogen receptor (ER).

IC50 value:
Target:
20S-Protopanaxatriol (g-PPT), a dammarane-type tetracyclic terpene sapogenin, may be used to study its binding to and modulation of cell function via glucocortoid (GR) and oestrogen (ER) receptors.